Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price target upped by equities research analysts at JPMorgan ...

Learn more about whether Blueprint Medicines Corporation or Zai Lab Limited is a better investment based on AAII's A+ ...

Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have been given an average rating of “Moderate Buy” by the ...

In 2023, the FDA approved Blueprint Medicines’ Ayvakit (avapritinib) as the first, only treatment for indolent systemic mastocytosis (ISM). In the third quarter of 2024, Ayvakit reported net ...

The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM ... and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing ...

Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...

Indolent Lymphoma Market Outlook 2025-2035 ... enables localized and targeted administration of drugs, which decreases systemic exposure and lowers adverse effects. Adjunct therapies like ...

After hours: January 31 at 4:32:18 PM EST Loading Chart for BPMC ...

41 St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis ...

2,11 Although the use of NSAIDs and corticosteroids generally can achieve remission in patients presenting with the monocyclic pattern of AOSD, the polycyclic systemic pattern or chronic arthritis is ...